1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.
暂无分享,去创建一个
K. Read | G. Tedesco | D. Minick | F. Micheli | Barbara Bertani | P. Cavanni | R. Di Fabio | L. Bettelini | I. Sartori | R. Arban | S. Fontana | G. Bonanomi | S. Braggio | A. Checchia | Silvia Terreni | L. Tarsi | Laura Zonzini | S. Davalli | Michele Negri | B. Oliosi | F. Visentini | C. Marchioro | E. Fazzolari | A. Zocchi | Michela Bettati | R. Benedetti | Anna Checchia
[1] M. Hascöet,et al. Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice , 2009, Psychopharmacology.
[2] C. Nemeroff,et al. Emerging targets for antidepressant therapies. , 2009, Current opinion in chemical biology.
[3] S. Kulkarni,et al. Current investigational drugs for major depression , 2009 .
[4] Saul Jaime-Figueroa,et al. Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. , 2008, Bioorganic & medicinal chemistry letters.
[5] P. Carlier,et al. Antidepressant-Like Pharmacological Profile of a Novel Triple Reuptake Inhibitor, (1S,2S)-3-(Methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS) , 2008, Journal of Pharmacology and Experimental Therapeutics.
[6] Brian Lord,et al. In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor. , 2008, European journal of pharmacology.
[7] P. Skolnick,et al. Triple uptake inhibitors: therapeutic potential in depression and beyond , 2007, Expert opinion on investigational drugs.
[8] C. Nemeroff. The burden of severe depression: a review of diagnostic challenges and treatment alternatives. , 2007, Journal of psychiatric research.
[9] G. Papakostas. Dopaminergic-based pharmacotherapies for depression , 2006, European Neuropsychopharmacology.
[10] C. Heidbreder,et al. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex , 2005, Neuroscience Letters.
[11] Джотам Уодсворт Коэ,et al. Preparation of 3-azabicyclo [3.1.0] hexane , 2004 .
[12] M. Millan. The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. , 2004, European journal of pharmacology.
[13] Julio Licinio,et al. From monoamines to genomic targets: a paradigm shift for drug discovery in depression , 2004, Nature Reviews Drug Discovery.
[14] J. Hyttel,et al. Pharmacology in vivo of the phenylindan derivative, lu 19-005, a new potent inhibitor of dopamine, noradrenaline and 5-hydroxytryptamine uptake in rat brain , 1985, Naunyn-Schmiedeberg's Archives of Pharmacology.
[15] A. Janowsky,et al. "Broad spectrum" antidepressants: is more better for the treatment of depression? , 2003, Life sciences.
[16] A. Janowsky,et al. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. , 2003, European journal of pharmacology.
[17] Йерген Шель-Крюгер,et al. Tropane derivatives, their preparation and use , 1997 .
[18] G. Rigdon,et al. Potentiation of the behavioral effects of 5‐hydroxytryptophan by BW 1370U87, a selective monoamine oxidase‐A inhibitor , 1992 .
[19] G. Martin,et al. Mouse locomotor activity: an in vivo test for dopamine autoreceptor activation. , 1984, The Journal of pharmacology and experimental therapeutics.